EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of Mycobacterium tuberculosis in a new pharmacokinetic in vitro intracellular infection model



Treatment of Mycobacterium tuberculosis in a new pharmacokinetic in vitro intracellular infection model



Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 39: 26




(PDF 0-2 workdays service: $29.90)

Accession: 035980541

Download citation: RISBibTeXText



Related references

Evaluation of an intracellular pharmacokinetic in vitro infection model as a tool to assess tuberculosis therapy. International Journal of Antimicrobial Agents 29(2): 212-216, 2007

Pharmacokinetic-pharmacodynamic relationships for fluoroquinolones in an aerosol infection model with Mycobacterium tuberculosis. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 10, 2003

Establishment of an in vitro model using NR8383 cells and Mycobacterium bovis Calmette-Guerin that mimics a chronic infection of Mycobacterium tuberculosis. In Vivo 19(5): 821-830, 2005

Development of infection model for studying intracellular gene expression of Mycobacterium tuberculosis. African Journal of Medicine and Medical Sciences 38(4): 325-332, 2010

Abnormal immune responses in persons with previous extrapulmonary tuberculosis in an in vitro model that simulates in vivo infection with Mycobacterium tuberculosis. Clinical and Vaccine Immunology 19(8): 1142-1149, 2012

Assessment of in vitro immunity to Mycobacterium tuberculosis in a human peripheral blood infection model using a luciferase reporter construct of M. tuberculosis H37Rv. Clinical and Experimental Immunology 145(3): 520-527, 2006

Killing of Mycobacterium avium and Mycobacterium tuberculosis by a mycobacteriophage delivered by a nonvirulent mycobacterium: a model for phage therapy of intracellular bacterial pathogens. Journal of Infectious Diseases 186(8): 1155-1160, 2002

Synthesis, characterization and in vitro extracellular and intracellular activity against Mycobacterium tuberculosis infection of new second-line antitubercular drug-palladium complexes. Journal of Pharmacy and Pharmacology 66(1): 106-121, 2014

Population pharmacokinetic/pharmacodynamic analysis of the bactericidal activities of sutezolid (PNU-100480) and its major metabolite against intracellular Mycobacterium tuberculosis in ex vivo whole-blood cultures of patients with pulmonary tuberculosis. Antimicrobial Agents and ChemoTherapy 58(6): 3306-3311, 2015

Human splenic macrophages as a model for in vitro infection with Mycobacterium tuberculosis. Tuberculosis 87(6): 509-517, 2007

Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis. Infection and Immunity 74(3): 1718-1724, 2006

An in vitro model of the leukocyte interactions associated with granuloma formation in Mycobacterium tuberculosis infection. Immunology and Cell Biology 85(2): 160-168, 2007

An in vitro tissue culture bilayer model to examine early events in Mycobacterium tuberculosis infection. Infection and Immunity 67(2): 653-658, 1999

Killing of Mycobacterium avium and Mycobacterium tuberculosis by a mycobacteriophage delivered by avirulent mycobacteria A model for phage therapy of intracellular bacterial pathogens. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 64, 2001

Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. Journal of Infectious Diseases 190(9): 1642-1651, 2004